Caricamento...
EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?
Broncho-pulmonary neuroendocrine neoplasms (BP-NENs) are neoplasms orphan of an efficient therapy. Available medical treatments derived from clinical trials are not specific for the management of this malignancy. Sunitinib is a multi-receptor tyrosine-kinases (RTKs) inhibitor that has already shown...
Salvato in:
| Pubblicato in: | Endocr Connect |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Bioscientifica Ltd
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6528406/ https://ncbi.nlm.nih.gov/pubmed/31035254 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EC-19-0192 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|